Latest Neurogenesis Stories
ROCKVILLE, Md., June 7, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan (SPI), a wholly owned subsidiary of Sumitomo Corporation Group.
Hippocampal stems cells for use in neuroscience and cytotoxicity testing. Branford, CT (PRWEB) May 11, 2011 GigaCyte, LLC., a leading provider of human stem cell-based products and preclinical contract research services, headquartered in Branford, Connecticut USA, announced the launch of human hippocampal stem cells for use in neuroscience and cytotoxicity testing.
Abundant precursor cells can become many types of neurons without introducing tumor risk.
ROCKVILLE, Md., April 20, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.
British scientists using human stem cells claim to have discovered how antidepressants create new brain cells, helping drug researchers develop more efficient medicines to fight depression.
A group of scientists at Marshall University is conducting research that may someday lead to new treatments for repair of the central nervous system.
Two studies published by an interdisciplinary team of Hong Kong researchers in the current special issue of Cell Transplantation (20:1), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , link the regrowth of key adult brain cells (neurogenesis) in two critical areas of the brain to both the benefits of exercise as a stress reducer and also to sexual behavior and reproductive issues.
Northwestern Medicine researchers for the first time have transformed a human embryonic stem cell into a critical type of neuron that dies early in Alzheimer's disease and is a major cause of memory loss.
ROCKVILLE, Md., March 1, 2011 /PRNewswire/ -- Neuralstem, Inc. (Amex: CUR) announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications.
ROCKVILLE, Md., Feb. 9, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that the U.S.